For example, a recurrent locus mutated in VEXAS patients, Y55 [14, 31, 42], has recently been shown to be the site of phosphorylation by SRC (SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase), which affects ubiquitin activation efficiency [43]. The gene discussed is SRC; the disease is VEXAS syndrome.